

## Information on Voting Rights and Denominator

**Liège, Belgium – January 9<sup>th</sup>, 2025, 06.30 PM CET – Regulated information**– In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings in issuers whose shares are admitted to trading on a regulated market Hyloris Pharmaceuticals SA publishes the below information following the expiry of a warrant plan set up for Company employees and managers.

- Total Share capital: EUR 140,001.87
- Total number of securities carrying voting rights: 28,000,374 (all ordinary shares)
- Total number of voting rights (= denominator): 28,000,374 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
  - Pursuant to the ESOP Warrants plan of November 27, 2020: 185,500 subscription rights giving right to 185,500 ordinary shares
  - Pursuant to the ESOP Warrants plan of June 22, 2022: 123,813 subscription rights giving right to 123,813 ordinary shares
  - In total 309,313 subscription rights giving right to 309,313 ordinary shares (all granted)

\*\*\*

### For more information, contact Hyloris:

Stijn Van Rompay, Co-CEO  
Stijn.vanrompay@hyloris.com  
+32 (0)4 346 02 07

Thomas Jacobsen, Co-CEO  
Thomas.jacobsen@hyloris.com





## **About Hyloris Pharmaceuticals SA**

Hyloris is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address important healthcare needs and deliver relevant improvements for patients, healthcare professionals and payors.

The Company's development strategy primarily focuses on leveraging existing regulatory pathways, such as the FDA's 505(b)2 pathway in the U.S or similar regulatory frameworks in other region which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This type of regulatory pathway can reduce the clinical burden required to bring a product to market, significantly shorten the development timelines and reduce costs and risks.

Hyloris has built a broad, patented portfolio of 19 reformulated and repurposed value-added medicines that have the potential to offer significant advantages over available alternatives. Two products are currently in early phases of commercialization with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. Outside its core strategic focus, the Company also has 1 approved high barrier generic product launched in the U.S. and 2 high barrier generic products in development.

Hyloris is based in Liège, Belgium. For more information, visit [www.hyloris.com](http://www.hyloris.com) and follow-us on LinkedIn.

